Mizuho Securities Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating
Adaptimmune Therapeutics: Strategic Restructuring and Promising Developments Drive 'Buy' Rating
Adaptimmune Therapeutics Analyst Ratings
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.5
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations